Project Grant R01CA311678
Award Date 6/2/26
Completion Date 5/31/31
Dollars Obligated $561K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90033, USA
Similar Awards
- Federal Grant Award Summary The University of Southern California received a $581,548 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded June 2, 2026, with completion targeted for May 31, 2031. This award funds research to elucidate the therapeutic mechanisms of Werner (WRN) protein targeting in microsatellite instability (MSI) colorectal cancer cells. The research employs a synthetic lethality strategy to investigate how WRN...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California $479,234 under the Cancer Biology Research program (CFDA 93.396) to conduct a comprehensive research initiative examining nonsense-mediated mRNA decay (NMD) mechanisms in cancer. Spanning from May 15, 2026, to April 30, 2031, this project delivers fundamental research services aimed at understanding NMD's regulatory functions beyond its conventional role in degrading faulty mRNA...
- Federal Grant Award Summary The University of Southern California received a $680,452 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective June 9, 2026, with a completion date of May 31, 2029. This research initiative focuses on discovering novel small-molecule compounds that selectively target the BMAL1:CLOCK circadian regulatory complex for cancer therapeutic applications. The project addresses a significant gap in drug...
- Federal Project Grant Award Summary The University of Southern California received a $1,283,835 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded July 1, 2025, with a completion date of June 30, 2030. This grant supports the development and translational advancement of IMT-423 (MHC-II-Restricted CT83-Specific CD4-Dependent TCRM50A-STEM2) T cells, a novel T cell receptor (TCR)-engineered CD4+ T cell immunotherapy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Medical University of South Carolina (MUSC) a Project Grant totaling $643,053 under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This award supports fundamental research investigating the novel kinase-independent functions of cyclin D3 in T cells and its implications for tumor progression and immunotherapy efficacy. The research addresses critical barriers...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $501,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) commencing May 1, 2026, with completion targeted for April 30, 2031. This award supports fundamental research to advance understanding of synthetic lethal (SL) vulnerabilities in specific cancer subtypes, with the ultimate objective of developing novel precision oncology therapeutics. The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Southern California a $3,036,844 Project Grant on August 11, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate a wireless thermos-activator device for controllable solid tumor immunotherapy. The project addresses critical limitations in Chimeric Antigen Receptor (CAR) T cell therapy by creating a portable, patient-friendly alternative to MRI-guided...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through July 31, 2032. The award supports research into new approaches for targeting cell cycle proteins in cancer treatment, specifically focusing on cyclin-dependent kinase (CDK) inhibitor development and therapeutic applications. The research addresses critical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Project Grant Award Summary The University of Southern California received a $137,459 Cancer Research Manpower (CFDA 93.398) award from the National Cancer Institute, effective June 1, 2026 through May 31, 2029. This K01 mentored research development award supports an integrated training and research project focused on developing a spatially controlled priming system for chimeric antigen receptor (CAR) T cell therapy in solid tumors. The award funds research to engineer a focused...